Tonix Pharmaceuticals (TNXP) Holding announced the expansion of its leadership team to support the launch of TNX-102 SL for the management of fibromyalgia. Bradley Raudabaugh, MBA, has been appointed Vice President, VP, Marketing, and Errol Gould, Ph.D., has been appointed Vice President, Medical Affairs. New Drug Application for TNX-102 SL for the management of fibromyalgia submitted to FDA in October 2024; NDA acceptance expected December 2024; Fast Track designation previously granted by FDA; FDA decision on approval expected 2025
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNXP:
- Biotech Alert: Searches spiking for these stocks today
- Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects
- Tonix Pharma Reveals Promising TNX-801 Vaccine Data
- Tonix Pharmaceuticals announces publication of study on tolerability of TNX-801
- Tonix Pharmaceuticals reports Q3 EPS (23c), consensus ($2.93)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
